Federal legislation and the advancement of neonatal drug studies

Journal of Pediatrics

Volumn 162, Issue 1, 2013, Pages 12-15

  Wiles, Jason R ^a   Vinks, Alexander A ^a,b   Akinbi, Henry ^a,b  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Best Pharmaceuticals for Children Act; BPCA; FDA; FDA Modernization Act; FDAMA; Food and Drug Administration; National Institute of Child Health and Human Development; NICHD; Pediatric Pharmacology Research Unit; Pediatric Research Equity Act; PPRU; PREA

Indexed keywords

ADAPTATION; BODY COMPOSITION; CHILD SAFETY; CLINICAL TRIAL (TOPIC); DRUG DEVELOPMENT; DRUG LABELING; DRUG LEGISLATION; DRUG SAFETY; DRUG SCREENING; EVIDENCE BASED MEDICINE; HUMAN; NOTE; ONTOGENY; PHARMACODYNAMICS; PHARMACOKINETICS; PREMATURITY; PRIORITY JOURNAL;

CHILD; CLINICAL TRIALS AS TOPIC; DRUG EVALUATION; HUMANS; LEGISLATION, DRUG; UNITED STATES;

EID: 84871363680     PISSN: 00223476     EISSN: 10976833     Source Type: Journal    
DOI: 10.1016/j.jpeds.2012.08.034     Document Type: Note

References (43)

1. J. Avorn Learning about the safety of drugs: a half-century of evolution N Engl J Med 365 2011 2151 2153
2. US Congress Drug amendments of 1962. Public Law 87-781 1962 GPO Washington p. 76
3. J.M. Sutherland Fatal cardiovascular collapse of infants receiving large amounts of chloramphenicol AMA J Dis Child 97 1959 761 767
4. D.H. Andersen, W.A. Blanc, D.N. Crozier, and W.A. Silverman A difference in mortality rate and incidence of kernicterus among premature infants allotted to two prophylactic antibacterial regimens Pediatrics 18 1956 614 625
5. J.M. Sutherland, and W.H. Keller Novobiocin and neonatal hyperbilirubinemia: an investigation of the relationship in an epidemic of neonatal hyperbilirubinemia Arch Pediatr Adolesc Med 101 1961 447 453
6. L. Johnson, F.W. Bowen Jr., S. Abbasi, N. Herrmann, M. Weston, and L. Sacks Relationship of prolonged pharmacologic serum levels of vitamin E to incidence of sepsis and necrotizing enterocolitis in infants with birth weight 1,500 grams or less Pediatrics 75 1985 619 638 (Pubitemid 15079510)
7. S.J. Yaffe Antibiotics for the newborn infant; a discussion of dosages Clin Pediatr (Phila) 4 1965 639 643
8. A.F. Robertson Reflections on errors in neonatology: II. The "heroic" years, 1950 to 1970 J Perinatol 23 2003 154 161 (Pubitemid 36511745)
9. G.P. Giacoia, D.L. Birenbaum, H.C. Sachs, and D.R. Mattison The newborn drug development initiative Pediatrics 117 2006 S1 S8
10. G.P. Giacoia, and D.R. Mattison Selected proceedings of the NICHD/FDA newborn drug development initiative: part II Clin Ther 28 2006 1337 1341 (Pubitemid 44585281)
11. US Congress Food and Drug Administration Modernization Act of 1997. Public Law 105-115 1997 GPO Washington p. 111
12. US Congress Best Pharmaceuticals for Children Act. Public Law 107-109 2002 GPO Washington p. 115
13. US Congress Pediatric Research Equity Act of 2003. Public Law 108-155 2003 GPO Washington p. 117
14. R.M. Ward, and R. Kauffman Future of pediatric therapeutics: reauthorization of BPCA and PREA Clin Pharmacol Ther 81 2007 477 479 (Pubitemid 46452311)
15. US National Institutes of Health. Pediatric pharmacology research units (PPRU) legacy. http://ppru.org. Accessed January 26, 2012.
16. US Food and Drug Administration. Best Pharmaceuticals for Children (BPCA) priority list of needs in pediatric therapeutics. http://bpca.nichd.nih.gov/ about/process/upload/2011-Priority-List-and-Summary-for-web-posting-04-07-11. pdf. Accessed December 29, 2011.
17. US Food and Drug Administration. Pediatric exclusivity labeling changes. http://www.fda.gov/downloads/ScienceResearch/SpecialTopics/ PediatricTherapeuticsResearch/UCM163159.pdf. Accessed December 29, 2011.
18. R.M. Ward, and S.E. Kern Clinical trials in neonates: a therapeutic imperative Clin Pharmacol Ther 86 2009 585 587
19. L. James, and S. Ito Neonatal pharmacology: rational therapeutics for the most vulnerable Clin Pharmacol Ther 86 2009 573 577
20. US National Institutes of Health. ClinicalTrials.gov Registry. www.clinicaltrials.gov. Accessed March 12, 2012.
21. H. Shirkey Therapeutic orphans J Pediatr 72 1968 119 120
22. A.A. Mitchell, P. Goldman, S. Shapiro, and D. Slone Drug utilization and reported adverse reactions in hospitalized children Am J Epidemiol 110 1979 196 204 (Pubitemid 10209703)
23. S. Kumar Adverse drug reactions in the newborn Ann Clin Lab Sci 15 1985 195 203 (Pubitemid 15123086)
24. J. Mason, M. Pirmohamed, and T. Nunn Off-label and unlicensed medicine use and adverse drug reactions in children: a narrative review of the literature Eur J Clin Pharmacol 68 2012 21 28
25. P.J. Johnson Neonatal pharmacology: pharmacokinetics Neonatal Netw 30 2011 54 61
26. T. Yokoi Essentials for starting a pediatric clinical study (1): pharmacokinetics in children J Toxicol Sci 34 Suppl 2 2009 SP307 SP312
27. M. Sonnier, and T. Cresteil Delayed ontogenesis of CYP1A2 in the human liver Eur J Biochem 251 1998 893 898 (Pubitemid 28108986)
28. I. Choonara, and S. Conroy Unlicensed and off-label drug use in children: implications for safety Drug Saf 25 2002 1 5 (Pubitemid 34208327)
29. G.W. t Jong, A.G. Vulto, M. de Hoog, K.J. Schimmel, D. Tibboel, and J.N. van den Anker Unapproved and off-label use of drugs in a children's hospital N Engl J Med 343 2000 1125
30. J. Barr, G. Brenner-Zada, E. Heiman, G. Pareth, M. Bulkowstein, and R. Greenberg Unlicensed and off-label medication use in a neonatal intensive care unit: a prospective study Am J Perinatol 19 2002 67 72 (Pubitemid 34229581)
31. R.H. Clark, B.T. Bloom, A.R. Spitzer, and D.R. Gerstmann Reported medication use in the neonatal intensive care unit: data from a large national data set Pediatrics 117 2006 1979 1987 (Pubitemid 46071242)
32. Institute of Medicine Safe and effective medicines for children: pediatric studies conducted under the Best Pharmaceuticals for Children Act and the Pediatric Research Equity Act 2012 National Academies Press Washington, DC
33. US National Institutes of Health. Pediatric trials network. http://pediatrictrials.org. Accessed March 15, 2012.
34. G.P. Giacoia, and D.R. Mattison Newborns and drug studies: the NICHD/FDA newborn drug development initiative Clin Ther 27 2005 796 813 (Pubitemid 41583528)
35. Committee on Clinical Research Involving Children Ethical Conduct of clinical research involving children M.J. Field, and R.E. Behrman Ethical conduct of clinical research involving children 2004 Committee on Clinical Research Involving Children Washington, DC
36. R.M. Ward, W.E. Benitz, D.K. Benjamin Jr., L. Blackmon, G.P. Giacoia, and M. Hudak Criteria supporting the study of drugs in the newborn Clin Ther 28 2006 1385 1398 (Pubitemid 44585284)
37. US Food and Drug Administration. Guidance for industry: exposure-response relationships - study design, data analysis, and regulatory applications. www.fda.gov/downloads/Drugs/GuidanceCompianceRegulatoryInformation/Guidances/ ucm072109.pdf. Accessed December 15, 2011.
38. M. Rowland, C. Peck, and G. Tucker Physiologically-based pharmacokinetics in drug development and regulatory science Annu Rev Pharmacol Toxicol 51 2011 45 73
39. J.S. Leeder Developmental pharmacogenetics: a general paradigm for application to neonatal pharmacology and toxicology Clin Pharmacol Ther 86 2009 678 682
40. M. Cella, W. Zhao, E. Jacqz-Aigrain, D. Burger, M. Danhof, and O. Della Pasqua Paediatric drug development: are population models predictive of pharmacokinetics across paediatric populations? Br J Clin Pharmacol 72 2011 454 464
41. M. Mouksassi, J. Marier, J. Cyran, and A. Vinks Clinical trial simulations in pediatric patients using realistic covariates: application to teduglutide, a glucagon-like peptide-2 analog in neonates and infants with short-bowel syndrome Clin Pharmacol Ther 86 2009 667 671
42. Hearing on reauthorization of PDUFA: What it means for jobs, innovation, and patients. Washington, DC: Energy and Commerce Committee, Health Subcommittee. 112th Congress, 2nd Session; 2012 (testimony of Daniel Frattarelli).
43. A.A. Vinks Important role of population pharmacokinetic/pharmacodynamic modeling in pediatric therapeutics J Pediatr 159 2011 361 363